natgillin/translations-raw huggingface dataset:
48 hours from date and time of End of Synthesis (EOS).
48 ur od datuma in časa konca sinteze.
Liver, kidney and the intestinal tract reached their maximal content of Copper-64 within the first few hours, and then radioactivity steadily diminished.
Jetra, ledvice in črevesje so dosegli največjo vsebnost bakra (64Cu) v prvih nekaj urah, nato se je radioaktivnost enakomerno zmanjševala.
Almost the entire 64CuCl2 rapidly leaves the blood and enters the liver and kidney.
Skoraj ves bakrov klorid (64CuCl2) se hitro očisti iz krvi ter vstopi v jetra in ledvice.
This will enable the generation of further pharmacovigilance data which will provide assurance that risks for this product are detected and adequately characterised in the post-marketing setting.
S tem se bodo pridobili nadaljnji farmakovigilančni podatki in tako se bo zagotovilo, da so tveganja povezana z zdravilom v obdobju trženja zdravila odkrita in ustrezno opisana.
It must be considered that the radiolabelled medicinal product emits high intensity Auger electrons.
Treba je upoštevati, da radioaktivno označeno zdravilo oddaja Augerjeve elektrone visokih intenzivnosti.
The minimal specific activity is 3,700 MBq Copper-64/micrograms of Copper at the expiry date and time.
Minimalna specifična aktivnost je 3.700 MBq bakra-64/mikrogram bakra na datum in čas izteka roka uporabnosti.
The use of Copper-64-labelled medicinal products is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded (see section 4.3).
Uporaba z bakrom (64Cu) označenih zdravil je kontraindicirana ob ugotovljeni nosečnosti ali sumu nanjo ali kadar nosečnost ni bila izključena (glejte poglavje 4. 3).
This medicinal product must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
To zdravilo se sme uporabljati samo za radioaktivno označevanje nosilnih molekul, ki so bile posebej razvite in odobrene za radioaktivno označevanje s tem radionuklidom.
Measurements on the location and during work are critical and should be practiced for more precise and instructive determination of overall radiation dose to the staff.
Pomembno je, da se izvajajo meritve na kraju dela in med delom, saj se s tem lahko natančneje in bolj poučno določi skupni odmerek sevanja za osebje.
Storage of radiopharmaceuticals should be in accordance with national regulation on radioactive materials.
Shranjevanje radiofarmakov mora biti v skladu z nacionalnimi določili za radioaktivne materiale.
Copper chloride (64CuCl2) is distributed mainly in the liver and kidney and the pattern of radioactivity in the blood parallels the pattern of radioactivity in the liver.
Bakrov klorid (64CuCl2) se porazdeli predvsem v jetra in ledvice, torej je vzorec radioaktivnosti v krvi vzporeden z vzorcem radioaktivnosti v jetrih.
Cuprymina is stored under the responsibility of the specialist in appropriate premises.
Radionukleotidni predhodnik Cuprymina se shranjuje v pristojnosti strokovnjaka v za to ustreznih prostorih.
These chelating agents help elimination of copper radiotoxicity by an exchange between the calcium ion and the copper due to their capacity of forming water soluble complexes with the chelating ligands (DTPA, EDTA).
Ti kelatorji zavirajo radiotoksičnost bakra z izmenjavo kalcijevih ionov in bakrom na podlagi zmožnosti bakra, da z ligandi za kelatiranje (DTPA, EDTA) tvori v vodi topne komplekse.
Non-clinical data reveal no special hazard for humans based on available published data.
Predklinični podatki na podlagi razpoložljivih objavljenih podatkov ne kažejo posebnega tveganja za človeka.
When an administration of radioactive medicinal products to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant.
Pri načrtovanem dajanju radiofarmaka ženskam v rodni dobi je pomembno ugotoviti, ali je ženska noseča.
Copper-64 decays by an emission of β+ (17.6 %) with a maximum energy of 0.66 MeV, an emission of β- (38.5 %) with a maximum energy of 0.58 MeV and electronic capture (43.9 %).
Baker-64 razpada z oddajanjem delcev β+ (17,6 %) z najvišjo energijo 0,66 MeV, oddajanjem delcev β- (38,5 %) z najvišjo energijo 0,58 MeV in zajetjem elektronov (43,9 %).
When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.
Če ste v dvomih, je pomembno, da se posvetujete s specialistom nuklearne medicine, ki bo postopek nadzoroval.
Only syringe needles (for example, non-metallic) with proven resistance to dilute acid should be used to minimise trace metal impurity levels.
Uporabljajo se lahko samo igle za brizge (npr. nekovinske) z dokazano odpornostjo proti razredčenim kislinam, s čimer se zmanjša stopnja prisotnosti sledov kovinskih nečistot.
For in vitro radiolabelling.
Za radioaktivno označevanje in vitro.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Volume: {Z} mL
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT Prostornina: {Z} ml
The radiation dose to the patient resulting from exposure after administration may result in higher incidence of cancer and mutations.
Prejeti odmerek sevanja zaradi terapevtske izpostavljenosti lahko pri bolniku povzroči večjo pojavnost raka in mutacij.
Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects.
Izpostavljanje ionizirajočemu sevanju je povezano s povzročitvijo raka in pomeni možnost za razvoj dednih okvar.
Cuprymina should be received, used and administered only by authorised persons in designated clinical settings.
Cuprymina sme sprejemati, uporabljati in dajati samo pooblaščeno osebje v izbranih kliničnih ustanovah.
For this reason it is mandatory to use protective high quality (latex/nitrile) gloves in any direct contact with the radiopharmaceutical (vial/syringe) and with the patient.
Zato je pri vsakem neposrednem stiku z radiofarmakom (viala/brizga) in z bolnikom obvezna uporaba visokokakovostnih zaščitnih rokavic (iz lateksa/nitrila).
Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the radiopharmaceutical outweighs the risk from radiation.
Osebni zdravnik in zdravnik nuklearne medicine menita, da klinične koristi postopkov z radiofarmakom odtehtajo tveganja zaradi sevanja.
It is not known whether copper (64Cu) chloride may interact with other medicines as specific studies have not been carried out.
Medsebojno delovanje bakrovega (64Cu) klorida z drugimi zdravili ni poznano, ker posebne študije niso bile izvedene.
The Copper-64 gamma dose constant is 3.6 x 10-5 mSv x MBq-1 x h at a distance of 1 meter.
Na razdalji 1 metra je konstanta bakrovega (64Cu) odmerka gama 3,6 x 10-5 mSv x MBq-1 x h. V
Copper-64 decays in stable Nickel 64Ni (61 %) by an emission of β+ (18 %) or by an electronic capture (43 %).
Baker-64 razpade v stabilen nikelj 64Ni (61 %) z oddajanjem delcev β+ (18 %) ali z zajetjem elektronov (43 %).
After the medicine radiolabelled with Cuprymina is administered, it will deliver certain amounts of ionising radiation (radioactivity) which can induce a certain risk of cancer and development of hereditary defects.
Po dajanju zdravila, radioaktivno označenega z radiofarmacevtskim predhodnikom Cuprymina, boste prejeli določeno količino ionizirajočega sevanja (radioaktivnosti), kar lahko povzroči določeno tveganje za raka in razvoj genetskih okvar.
The following preparations must be available in medical institutions, which use Cuprymina for labelling of carrier molecules: - Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or - Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
V zdravstvenih ustanovah, v katerih za označevanje nosilnih molekul uporabljajo radionukleotidni predhodnik Cuprymina, morajo biti na razpolago naslednji pripravki: - Ca-DTPA (trinatrijev kalcijev dietilentriamin pentaacetat) ali - Ca-EDTA (kalcijev dinatrijev etilendiamin tetraacetat).
If you have been given more medicine radiolabelled with Cuprymina than you should Since the medicine radiolabelled with Cuprymina is handled by a nuclear medicine doctor under strictly controlled conditions, there is only a very small chance of possible overdose.
Ker z zdravilom, radioaktivno označenim z radiofarmacevtskim predhodnikom Cuprymina, ravna le zdravnik nuklearne medicine pod strogo nadzorovanimi pogoji, obstaja zelo majhno tveganje za morebiten prevelik odmerek.
When the precursor is bound to a carrier molecule the content of radioactive free copper is supposed to be less than the stated amounts depending on the carrier used.
Ko je predhodnik vezan na nosilno molekulo, naj bi bilo radioaktivnega prostega bakra manj od navedenih količin, odvisno od vrste nosilne molekule.
Part of the decrease can be attributed to excretion of Copper-64 into the bile, urine and faeces.
Delno zmanjšana radioaktivnost se lahko pripiše izločanju bakra (64Cu) v žolč, urin in blato.
The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting, etc.
Dajanje radiofarmakov pomeni tveganje za druge osebe zaradi izpostavljenosti zunanjemu sevanju ali kontaminacije zaradi razlitja urina, bruhanja ipd.
Copper-64 decays also in stable Zinc (64Zn) by emission of β- (39 %).
Baker-64 razpade tudi v stabilen cink (64Zn) z oddajanjem delcev β- (39 %).
Pharmacokinetics of Cuprymina was investigated in mice.
Farmakokinetika radiofarmacevtskega predhodnika Cuprymina je bila raziskana na miših.
Like all medicines, the medicine radiolabelled with Cuprymina can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo, radioaktivno označeno z radiofarmacevtskim predhodnikom Cuprymina, neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Duration of the procedure
in izvedba postopka
The use of Copper-64-labelled medicines involves exposure to small amounts of radioactivity.
Uporaba zdravil, označenih z bakrom (64Cu), vključuje izpostavljenost majhnim količinam radioaktivnosti.
Children and adolescents Medicines radiolabelled with Cuprymina should not be used in children and adolescents up to 18 years.
Zdravila, radioaktivno označena z radiofarmacevtskim predhodnikom Cuprymina, se ne smejo uporabljati pri otrocih in mladostnikih, starih do 18 let.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given medicines radiolabelled with Cuprymina.
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s specialistom nuklearne medicine, preden prejemete zdravilo, radioaktivno označeno z radiofarmacevtskim predhodnikom Cuprymina.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Predpisovanje in izdaja zdravila je le pod omejenimi pogoji in na recept (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
The toxicity of the free Copper-64 due to in vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents.
Toksičnost prostega bakra (64Cu) zaradi in vivo sproščanja iz označene biomolekule v telesu med terapijo se lahko zmanjša z naknadnim dajanjem kelatorjev.
Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements.
Radiofarmake je treba pripraviti na način, ki bo zadoščal tako zaščiti pred sevanjem in tudi farmacevtskim zahtevam po kakovosti.
No interactions studies of Copper-64 chloride with other medicinal products have been performed.
Študij medsebojnega delovanja bakrovega (64Cu) klorida z drugimi zdravili niso izvedli.
The nuclear medicine doctor supervising the procedure will decide on the quantity of medicine radiolabelled with Cuprymina to be used in your case.
Zdravnik nuklearne medicine, ki nadzira postopek, bo določil količino zdravila, radioaktivno označenega z radiofarmacevtskim predhodnikom Cuprymina, ki bo uporabljena v vašem primeru.
Tel: 0039.388.8735530 or 0039.0733.560354 Fax: 0039.0836.1975111 or 0039.0733.560376 E-mail: info@sparklepet.it
Tel.: 0039.388.8735530 ali 0039.0733.560354 Faks: 0039.0836.1975111 ali 0039.0733.560376 E-naslov: info@sparklepet.it
Assuming that the environmental background value is of 150 nSv/h, and requiring that the dose rate due to Copper-64 is lower than the environmental background the condition of negligible radioactivity in the patient is reached, in practice, 4 days after injection (dose rate 132 nSv/h) as shown in table 1.
Ob predpostavki, da je vrednost naravnega ozadja 150 nSv/h, in pogoju, da je odmerek zaradi bakra (64Cu) manjši kot naravno ozadje, je v praksi pri bolniku doseženo stanje zanemarljive radioaktivnosti
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- Če imate dodatna vprašanja, se posvetujte s specialistom nuklearne medicine, ki bo nadzoroval postopek.
What Cuprymina looks like and contents of the pack Cuprymina is presented as a clear, and colourless solution filled in a 10 mL glass vial.
Izgled radiofarmacevtskega predhodnika Cuprymina in vsebina pakiranja Cuprymina je bistra in brezbarvna raztopina v 10-mililitrski steklo viali.
The radiopharmaceutical precursor solution is packaged in a colourless, type I glass 10 mL vial, closed with bromobutyl rubber stopper and aluminium overseal.
6.5 Vrsta ovojnine in vsebina Raztopina radiofarmacevtskega predhodnika je pakirana v brezbarvno stekleno (tip I) vialo s prostornino 10 ml, zaprto z zamaškom iz bromobutilne gume in aluminijasto zaščitno zaporko.
The dosimetry table below is presented in order to evaluate the contribution of non-conjugated Copper64 to the radiation dose following the administration of Copper-64-labelled medicinal product or resulting from an accidental intravenous injection of Cuprymina.
Spodnja preglednica dozimetrije predstavlja ocenjevanje prispevka nekonjugiranega bakra (64Cu) k prejetemu odmerku sevanja po dajanju z bakrom (64Cu) označenega zdravila ali kot rezultat naključne intravenske injekcije radiofarmacevtskega predhodnika Cuprymina.
It contains the active substance copper (64Cu) chloride.
Vsebuje učinkovino bakrov (64Cu) klorid.
The medicinal product must be aseptically withdrawn through the stopper using sterilised single-use needle and syringe after disinfecting the stopper.
Po dezinfekciji zaporke je treba izdelek z uporabo sterilne igle in brizge za enkratno uporabo aseptično odvzeti skozi zaporko.
Cuprymina should not be administered directly to the patient.
Radionukleotidni predhodnik Cuprymina se ne sme dajati neposredno bolniku.
Calibration time: {DD/MM/YYYY} 01h00 a.m. CET
Čas kalibracije: {DD/MM/LLLL} ob 1:00 po srednjeevropskem času
Specific activity ≥ 3,700 MBq Cu-64/micrograms of copper.
Specifična aktivnost ≥ 3.700 MBq bakra (64Cu)/mikrogram bakra
No animal toxicity studies were conducted with Cuprymina.
Toksikološke študije na živalih z radiofarmacevtskim predhodnikom Cuprymina niso bile izvedene.
The following information is intended for medical or healthcare professionals only: The complete Summary of Product Characteristics (SmPC) of Cuprymina is provided as a separate document in the medicinal product pack, with the objective to provide healthcare professionals with other additional scientific and practical information about the use of this medicinal product.
Celoten povzetek glavnih značilnosti zdravila za radionukleotidni predhodnik Cuprymina je na voljo kot ločen dokument v pakiranju zdravila, zato da zdravstveno osebje seznani z dodatnimi znanstvenimi in praktičnimi informacijami o ravnanju s tem zdravilom.
EXP {DD/MM/YYYY} hh:mm CET
EXP {DD/MM/LLLL} (hh:mm po srednjeevropskem času)
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended result.
Uporabljena radioaktivnost mora biti najnižja možna ob upoštevanju dejstva, da je treba doseči zastavljeni rezultat zdravljenja.
Other medicines and medicines radiolabelled with Cuprymina Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images.
Obvestite specialistom nuklearne medicine, če jemljete, ste pred kratkim jemali ali boste morda začeli jemati katero koli drugo zdravilo, saj lahko vplivajo na zdravnikovo razlago slik.
Relevant data is included in the Summary of Product Characteristics of the labelled medicinal products.
Pomembni podatki so vključeni v povzetek glavnih značilnosti zdravil, ki so radioaktivno označena.
The calibration time is set between the end of the synthesis time and the expiry time.
Čas kalibracije je nastavljen na čas po preteku sinteze in pred časom izteka roka uporabnosti.
One vial contains from 925 to 2,770 MBq (corresponding to 0.250.75 micrograms of copper-64).
Ena viala vsebuje od 925 do 2.770 MBq (kar ustreza 0,25-0,75 mikrograma bakra-64).
Should you have any further question on the use of Cuprymina, please ask the nuclear medicine doctor who supervises the procedure.
V primeru dodatnih vprašanj o uporabi radiofarmacevtskega predhodnika Cuprymina se posvetujte s specialistom nuklearne medicine, ki nadzoruje postopek.
Read all of this leaflet carefully before you are given the medicine combined with Cuprymina because it contains important information for you.
Pred začetkom uporabe zdravila, kombiniranega z radiofarmacevtskim predhodnikom Cuprymina, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
For this medicinal product, the effective dose resulting from an intravenously injected activity of 925 MBq is 65.86 mSv for a 60-kg female adult and 88.99 mSv for a 70-kg male adult.
65,86 mSv za 60 kilogramov težko odraslo žensko in 88,99 mSv za 70 kilogramov težkega odraslega moškega.
Cuprymina is only to be used by specialists experienced with in vitro radiolabelling
Radionukleotidni predhodnik Cuprymina smejo uporabljati le zdravniki specialisti, izkušeni na področju radioaktivnega označevanja in vitro.
The quantity of Cuprymina required for radiolabelling and the quantity of Copper-64-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
Količina radiofarmacevtskega predhodnika Cuprymina, potrebna za radioaktivno označevanje, in količina z bakrom (64Cu) označenega zdravila, ki je nato uporabljena, bo odvisna od radioaktivno označenega zdravila in njegove načrtovane uporabe.
Store in the original package that provides protection from radiation.
Shranjujte v originalni ovojnini, ki ščiti pred sevanjem.
Many international bodies assessed copper genotoxicity and carcinogenicity concluding that there is no conclusive evidence that copper may be mutagenic or carcinogenic The Scientific Committee on Food of the European Commission (2003) recommend a Dietary Allowances of 0.9 mg copper/day in adult males and females and established a Tolerable Upper Uptake level of 5 mg/day, allowing a huge safety margin in comparison to copper amount administered by Cuprymina.
Evropske komisije (2003) je priporočil prehranski vnos 0,9 mg bakra/dan za odrasle moške in ženske ter določil največji dovoljeni vnos 5 mg/dan, kar dopušča veliko varnostno rezervo v primerjavi s količino bakra, dobljenega z radiofarmacevtskim predhodnikom Cuprymina.
If you are pregnant Medicines radiolabelled with Cuprymina must not be administered if you are pregnant.
Zdravil, radioaktivno označenih z radiofarmacevtskim predhodnikom Cuprymina, ne smete jemati, če ste noseči.
Cuprymina is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound.
Radionukleotidni predhodnik Cuprymina se uporablja za radioaktivno označevanje, tehniko, pri kateri se učinkovina označi z radioaktivno snovjo.
The vials are packed into a tungsten or lead container for protective shielding.
Za zaščito so viale pakirane v volframovem ali svinčeno vsebniku.
Cuprymina is intended for in vitro radiolabelling of medicinal products, which are subsequently administered by the approved route.
Radionukleotidni predhodnik Cuprymina je namenjen za in vitro radioaktivno označevanje zdravil, ki se nato dajejo v skladu z odobreno potjo uporabe.
The volume of one vial ranges from 1 to 3 mL solution (corresponding to 925 to 2,770 MBq at calibration time).
Ena viala vsebuje od 1 do 3 ml raztopine (kar ustreza od 925 do 2.770 MBq ob času kalibracije).
Copper (64Cu) chloride
(64Cu) klorida.
Regarding the dose for a person in close contact with the patient, this is entirely due to the gamma rays (Cuprymina emits 2 gamma rays at 511.0 Kev and 1,345.77 Kev), because β+ and β- emissions have no role due to their very short range.
(radionukleotidni predhodnik Cuprymina oddaja 2 žarka gama pri 511,0 KeV in 1.345,77 KeV), saj je oddajanje delcev β in β zaradi kratkega dosega zanemarljivo.
absorbed dose per unit activity administered (mGy/MBq)
Absorbiran odmerek na enoto dane aktivnosti (mGy/MBq) organ odrasel moški (70 kg)
ULI wall heart wall kidneys liver lungs muscle ovaries pancreas red marrow 0.00581 0.00565 0.00670 0.0118 0.0242 0.0586 0.198 osteogenic cells skin spleen testes thymus thyroid urinary bladder wall 0.00 uterus effective dose ( Sv/1 GBq administered) adult male adult female 15 years 10 years 5 years 1 years newborn
stena srca ledvice jetra pljuča mišice jajčniki trebušna slinavka 0,00267 0,00310 0,00365 0,00716 0,00955 0,0199 0,0637 rdeči kostni mozeg 0,00581 0,00565 0,00670 0,0118 0,0242 0,0586 0,198 osteogene celice 0,00202 0,00269 0,00263 0,00426 0,00718 0,0172 0,0549 koža vranica testisi timus ščitnica stena sečnega mehurja maternica učinkovit odmerek (Sv/1 GBq)
Each vial contains an activity ranging from 925 MBq to 2,770 MBq (at calibration time) which corresponds to an amount of 0.25 to 0.75 micrograms of Copper-64.
Aktivnost na eno vialo je v razponu od 925 MBq do 2.770 MBq (ob času kalibracije), kar ustreza količini od 0,25 do 0,75 mikrograma bakra-64.
Individual benefit/risk justification
4.4 Posebna opozorila in previdnostni ukrepi Utemeljitev razmerja med koristjo in tveganjem pri posamezniku
What you need to know before the medicine radiolabelled with Cuprymina is used
Kaj morate vedeti, pred uporabo zdravila, radioaktivno označenega z radiofarmacevtskim predhodnikom Cuprymina
Information on radiation dosimetry of each different medicinal product following administration of the radiolabelled preparation is available in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Informacije o dozimetriji sevanja vsakega različnega zdravila po dodajanju radioaktivno označenega preparata so na voljo v povzetku glavnih značilnosti zdravila/navodilu za uporabo določenega zdravila, ki bo radioaktivno označeno.
Marketing Authorisation Holder SPARKLE S.r.l.
Imetnik dovoljenja za promet z zdravilom SPARKLE S.r.l.
Your nuclear medicine doctor will inform you about the usual duration of the procedure before the administration of the medicine radiolabelled with Cuprymina.
Trajanje postopka Zdravnik nuklearne medicine vas bo obvestil o običajnem trajanju postopka pred jemanju zdravila,
1 g of the chelating agents should be administered by slow intravenous injection over 3 - 4 minutes or by infusion (1 g in 100-250 mL of glucose, or sodium chloride 9 mg/mL (0.9 %) solution for injection).
100-250 ml glukoze ali v 0,9-odstotni (9 mg/ml) raztopini natrijevega klorida za injiciranje).
Pharmacokinetic data on Cuprymina relate to free copper
Farmakokinetični podatki za radionukleotidni predhodnik Cuprymina v zvezi s prostim bakrom
You will be asked to stop breast-feeding if you need to receive a medicine radiolabelled with Cuprymina.
Če dojite Rečeno vam bo, da prenehajte dojiti, če želite prejemati zdravilo radioaktivno označeno z Cuprymina.
Such information is supplied in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Te informacije so zbrane v povzetku glavnih značilnosti zdravila/navodilu za uporabo zdravila, ki bo radioaktivno označeno.